xevinapant
5 abstracts
Abstract
Xevinapant with radiation and concurrent carboplatin and paclitaxel in patients ineligible for cisplatin with locoregionally advanced squamous cell carcinoma of the head and neck (EXtRaCT study)Org: The University of Chicago Medicine Center for Advanced Care at Orland Park, University of Michigan,
Abstract
Phase 2 study of xevinapant + chemoradiotherapy (CRT) vs placebo + CRT in patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN): A post hoc activity analysis by blinded independent review committee evaluation.Org: Merck Serono Ltd., Merck, The Healthcare Business of Merck KGaA, Debiopharm, Institut Gustave Roussy,
Abstract
XRay Vision: A phase 3 study of xevinapant plus radiotherapy (RT) for high-risk, cisplatin-ineligible patients with resected, locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).Org: University of Pittsburgh Medical Center, University of Birmingham, Dana-Farber Cancer Institute, National Cancer Center Hospital East, Kashiwa, Japan, UCSF Medical Center-Mount Zion,
Abstract
Effect of extended treatment with IAP inhibitor xevinapant post radiotherapy (RT) on efficacy and the tumor microenvironment (TME) in preclinical models.Org: EMD Serono Research & Development Institute, Merck,
Abstract
Leveraging the mechanism of action (MOA) of xevinapant, an IAP inhibitor, for phase 3 dosing (RP3D) strategies in combination with radiation (RT) and chemoradiotherapy (CRT) in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).Org: EMD Serono Research & Development Institute, Debiopharm, Merck,